Trial Profile
Immunogenicity of influenza virus vaccine, meningococcal vaccines +/- secukinumab in adult subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 20 Feb 2013
Price :
$35
*
At a glance
- Drugs Secukinumab (Primary) ; Influenza virus vaccine; Meningococcal vaccine group C conjugate; Meningococcal vaccines
- Indications Influenza virus infections; Meningococcal infections; Rheumatoid arthritis
- Focus Pharmacodynamics
- Sponsors Novartis Institutes for BioMedical Research
- 29 Nov 2011 New trial record
- 09 Nov 2011 Results presented at the 75th Annual Scientific Meeting of the American College of Rheumatology and the 46th Annual Meeting of the Association of Rheumatology and Health Professionals.